Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
País/Región como asunto
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Infez Med ; 19(4): 224-34, 2011 Dec.
Artículo en Italiano | MEDLINE | ID: mdl-22212161

RESUMEN

A novel type of carbapenemase, New Delhi metallo beta-lactamase 1 (NDM 1), was first identified in 2008 in two Enterobacteriacea isolates, both recovered from a Swedish patient transferred from India. The emergence of NDM 1 is now reported from all continents, often in patients with a history of travel or hospitalization in the Indian subcontinent. The NDM 1 producing Gram-negative bacteria are mainly Enterobacteriaceae, which can cause colonization or fatal infections, with worrying antimicrobial susceptibility profiles: some isolates have developed resistance to practically all available antibiotics. Is the NDM-1 the super-bug? Are we in the post-antibiotic era? This review is a summary of currently available knowledge of NDM-1 that draws attention to future antimicrobial resistance scenarios.


Asunto(s)
Absceso/tratamiento farmacológico , Antibacterianos/uso terapéutico , Colistina/uso terapéutico , Complicaciones de la Diabetes , Infecciones por Klebsiella/tratamiento farmacológico , Klebsiella pneumoniae/efectos de los fármacos , beta-Lactamasas/metabolismo , Absceso/microbiología , Antibacterianos/farmacología , Nalgas , Colistina/farmacología , Farmacorresistencia Bacteriana Múltiple , Humanos , India , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/microbiología , Klebsiella pneumoniae/enzimología , Klebsiella pneumoniae/aislamiento & purificación , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Suecia , Viaje , Resultado del Tratamiento , beta-Lactamasas/efectos de los fármacos
2.
J Biol Regul Homeost Agents ; 10(1): 27-30, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-9049779

RESUMEN

Several experiments have suggested that the pineal gland has an antitumor immunomodulatory action. Melatonin (MLT), the best known pineal hormone, has been shown to stimulate anticancer immune defenses during the night, corresponding to the period of its maximum blood levels, whereas it has no effect during the light phase of the day. At present, no study has been performed to investigate possible immunomodulating properties of other pineal indoles, such as 5-methoxytryptophol (5-MTL), whose circadian secretion would be opposite with respect to that of MLT, since it reaches its highest levels during the light phase of the day. In an attempt to analyze possible effects of 5-MTL on anticancer immunity, we have evaluated the action of 5-MTL (1 mg/ day orally at noon for 5 days) in 10 healthy volunteers on the two fundamental suppressive and immunostimulatory cytokines, consisting of IL-6 and IL-2, respectively. Serum levels of IL-2 and IL-6 were measured by an immunoradiometric method. Mean serum concentrations of IL-2 significantly increased on 5-MTL therapy, whereas those of IL-6 significantly decreased in response to 5-MTL. This preliminary study would suggest that the less known pineal indole 5-MTL, as well as MLT, has important immunomodulatory effects on cytokine secretions, including those involved in the antitumor immune response, by further confirming the essential role of the pineal as a central regulation of biological response modifier system. Several pineal alterations have been described in advanced cancer patients. According to the results of this study, the simultaneous administration of MLT during the dark phase and of 5-MTL during the light period of the day could further contribute to correcting pineal functions and to pilot the host anticancer immune reaction in an antitumor direction with respect to MLT alone.


Asunto(s)
Adyuvantes Inmunológicos/farmacología , Indoles/farmacología , Interleucina-2/metabolismo , Interleucina-6/metabolismo , Glándula Pineal/fisiología , Adyuvantes Inmunológicos/administración & dosificación , Adyuvantes Inmunológicos/metabolismo , Administración Oral , Adulto , Ritmo Circadiano , Esquema de Medicación , Femenino , Humanos , Indoles/administración & dosificación , Interleucina-2/sangre , Interleucina-6/sangre , Masculino , Persona de Mediana Edad , Neoplasias/fisiopatología , Proyectos Piloto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA